# EDGAR Filing Document

**Accession Number:** 0001804598
**File Stem:** 0000899140-26-000620
**Filing Date:** 2026-6
**Character Count:** 11201
**Document Hash:** c6e29481bc0034c1def30eb41c506120
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899140-26-000620.hdr.sgml**: 20260601

**ACCESSION NUMBER**: 0000899140-26-000620

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260528

**FILED AS OF DATE**: 20260601

**DATE AS OF CHANGE**: 20260601

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Sukhtian Ghiath M.
- **CENTRAL INDEX KEY:** 0001717441

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37759
- **FILM NUMBER:** 261053379

**MAIL ADDRESS:**
- **STREET 1:** 7TH CIRCLE, ZAHRAN ST.
- **STREET 2:** ZAHRAN PLAZA BUILDING, 4TH FLOOR
- **CITY:** AMMAN
- **STATE:** M2
- **ZIP:** 11844
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GMS Ventures & Investments
- **CENTRAL INDEX KEY:** 0001804598

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37759
- **FILM NUMBER:** 261053378

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
- **STREET 2:** 190 ELGIN AVENUE
- **CITY:** GEORGE TOWN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-1104
- **BUSINESS PHONE:** 962 6 582 7999

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
- **STREET 2:** 190 ELGIN AVENUE
- **CITY:** GEORGE TOWN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-1104
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Outlook Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001649989
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 383982704
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**BUSINESS ADDRESS:**
- **STREET 1:** 111 S. WOOD AVENUE
- **STREET 2:** UNIT #100
- **CITY:** ISELIN
- **STATE:** NJ
- **ZIP:** 08830
- **BUSINESS PHONE:** 6096193990

**MAIL ADDRESS:**
- **STREET 1:** 111 S. WOOD AVENUE
- **STREET 2:** UNIT #100
- **CITY:** ISELIN
- **STATE:** NJ
- **ZIP:** 08830

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oncobiologics, Inc.
- **DATE OF NAME CHANGE:** 20150804

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Sukhtian Ghiath M.<br><sub>(Last) (First) (Middle)</sub><br>7TH CIRCLE, ZAHRAN ST.<br>ZAHRAN PLAZA BUILDING, 4TH FLOOR<br><sub>(Street)</sub><br>AMMAN, JORDAN 11844<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Outlook Therapeutics, Inc. [ OTLK ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GMS Ventures & Investments<br><sub>(Last) (First) (Middle)</sub><br>C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.<br>190 ELGIN AVENUE<br><sub>(Street)</sub><br>GEORGE TOWN, CAYMAN ISLANDS KY1-9007<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Outlook Therapeutics, Inc. [ OTLK ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-28 |  | P |  | 8539709<sup>(1)</sup> | A | $0.5855 | 22092068 | I | See footnote<sup>(2)(3)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrants (right to buy) | $2.26 | 2026-05-28 |  | H<sup>(4)</sup> |  |  | 3458571 | 2025-01-17 | 2030-01-17 | Common Stock | 3458571 | <sup>(4)</sup> | 0 | I | See footnote<sup>(2)(3)</sup> |
| Warrants (right to buy) | $0.5855 | 2026-05-28 |  | P<sup>(4)</sup> |  | 3458571 |  | 2025-01-17 | 2030-01-17 | Common Stock | 3458571 | <sup>(4)</sup> | 3458571 | I | See footnote<sup>(2)(3)</sup> |
| Warrants (right to buy) | $2.26 | 2026-05-28 |  | H<sup>(5)</sup> |  |  | 3458571 | 2025-03-11 | 2030-03-11 | Common Stock | 3458571 | <sup>(5)</sup> | 0 | I | See footnote<sup>(2)(3)</sup> |
| Warrants (right to buy) | $0.5855 | 2026-05-28 |  | P<sup>(5)</sup> |  | 3458571 |  | 2025-03-11 | 2030-03-11 | Common Stock | 3458571 | <sup>(5)</sup> | 3458571 | I | See footnote<sup>(2)(3)</sup> |
| Warrants (right to buy) | $1.4 | 2026-05-28 |  | H<sup>(6)</sup> |  |  | 8571428 | 2025-05-27 | 2030-05-27 | Common Stock | 8571428 | <sup>(6)</sup> | 0 | I | See footnote<sup>(2)(3)</sup> |
| Warrants (right to buy) | $0.5855 | 2026-05-28 |  | P<sup>(6)</sup> |  | 8571428 |  | 2025-05-27 | 2030-05-27 | Common Stock | 8571428 | <sup>(6)</sup> | 8571428 | I | See footnote<sup>(2)(3)</sup> |

---

### Footnotes:

(1) On May 28, 2026, GMS Ventures and Investments ("GMS Ventures") entered into a securities purchase agreement with Outlook Therapeutics, Inc. (the "Issuer") pursuant to which the Issuer agreed to issue and sell 8,539,709 shares of the Issuer's common stock at $0.5855 per share in a registered direct offering for a total purchase price of approximately $5.0 million.

(2) These securities are held of record by GMS Ventures. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization.

(3) By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(4) The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

(5) The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

(6) The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

**Signature:** /s/ Ghiath M. Sukhtian, By: Lawrence Kenyon, Attorney-in-Fact  
**Date:** 2026-06-01

**Signature:** /s/ GMS Ventures and Investments, By: Lawrence Kenyon, Attorney-in-Fact  
**Date:** 2026-06-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**